NSE · GML · Healthcare
Galaxy Medicare Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹40 Cr with net profit ₹3 Cr — a 8.37% net margin, versus 10.04% the period before.
Shareholding
As of 2026-03-31
- Promoter72.98%
- Public27.02%
867 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 3.56× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Healthcare · ranked #1 of 85 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Apollo Hospitals Enter. Limited | ₹1,26,078 Cr | 59.92 | 13.3 | 20.48% | 7.91% |
| Max Healthcare Institute Ltd. | ₹1,00,932 Cr | 67.43 | 9.39 | 13.42% | 16.73% |
| Manipal Health Enterpri Limited | ₹94,911 Cr | 101.2 | 5.78 | 10.59% | 7.81% |
| Fortis Healthcare Ltd. | ₹66,897 Cr | 62.71 | 6.76 | 10.53% | 11.02% |
| Aster DM Quality Care Ltd. | ₹66,465 Cr | 171.35 | 15.8 | 8.48% | 6.54% |
| Global Health Limited | ₹38,287 Cr | 66.89 | 9.66 | 14.05% | 11.88% |
| Narayana Hrudayalaya Ltd. | ₹38,187 Cr | 44.3 | 8.41 | 17.76% | 9% |
| Krishna Institute of Medical Sciences Ltd. | ₹33,258 Cr | 159.33 | 8.87 | 10.74% | 4.85% |
| Dr. Lal Path Labs Ltd. | ₹32,306 Cr | 57.44 | 12.88 | 20.13% | 18.75% |
| Poly Medicure Ltd. | ₹17,288 Cr | 54.02 | 5.57 | 10.37% | 15.77% |
| Galaxy Medicare Limited(this company) | — | 7.76 | 0.77 | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashGalaxy Medicare Limited (GML) has a PE ratio of 7.82 and an EPS of 2.25. The company's book value is 22.77 and its ROCE stands at 22.31%. Debt to equity is reported at 0.38. Its 52-week high was 54 and 52-week low was 15.15.
Positives
- +The company's ROCE of 22.31% indicates efficient use of capital.
- +Debt-to-equity ratio at 0.38 is relatively low.
- +Promoter holding is high at 72.9798% as of March 31, 2026.
- +No promoter shares are reported as pledged.
Negatives
- −Net profit decreased to Rs 3.3703 Cr in March 2025 from Rs 3.7074 Cr in March 2024.
- −EPS declined to 2.84 in March 2025 from 3.13 in March 2024.
- −Promoter holding decreased from 99.5659% in March 2025 to 72.9798% in March 2026.
- −No quarterly results have been disclosed.
Financial performance
Galaxy Medicare Limited reported revenue of Rs 40.2682 Cr in March 2025, an increase from Rs 36.9374 Cr in March 2024. Net profit for March 2025 was Rs 3.3703 Cr, down from Rs 3.7074 Cr in March 2024. Earnings per share (EPS) were 2.84 in March 2025, following 3.13 in March 2024.
Profitability & returns
The company's ROCE is 22.31%. Net profit for the year ending March 2025 was Rs 3.3703 Cr, declining from Rs 3.7074 Cr in March 2024. EPS for the same period was 2.84, a decrease from 3.13 in the prior year.
Balance sheet
Galaxy Medicare Limited has a debt-to-equity ratio of 0.38, indicating a moderate level of debt relative to equity. The book value per share is 22.77.
Ownership & pledges
Promoter holding in Galaxy Medicare Limited was 72.9798% as of March 31, 2026. Public shareholding was 27.0202%. There was no promoter pledge reported as of March 31, 2026. Institutional holdings were 0% for both DII and FII as of March 31, 2026.
Data as of — price: 2026-09-17 · financials: Mar 25 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.